Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;93(9):2166-2171.
doi: 10.1111/ans.18512. Epub 2023 May 20.

Can sarcopenia predict survival in locally advanced rectal cancer patients?

Richard Gartrell  1   2 , Jing Qiao  1 , Nicole Kiss  3   4 , Ian Faragher  1 , Steven Chan  2 , Paul N Baird  2   5 , Justin M Yeung  1   2
Affiliations

Can sarcopenia predict survival in locally advanced rectal cancer patients?

Richard Gartrell et al. ANZ J Surg. 2023 Sep.

Abstract

Background: There is mounting evidence that suggests sarcopenia can be used to predict survival outcomes in patients with colon cancer. However, the effect on locally advanced rectal cancer (LARC) is less clear. We sought to determine the association between sarcopenia on Overall Survival and Recurrence-free Survival (OS and RFS) in patients with LARC undergoing multimodal treatment.

Methods: A retrospective study was undertaken of all pre-treatment stage 2-3 rectal cancer patients who underwent neo-adjuvant treatment and surgery with curative intent between January 2010 and September 2016 at Western Health. Sarcopenia was measured on pre-treatment staging scans at the third lumbar vertebrae and defined using cohort-derived, sex-specific thresholds. Primary outcomes were OS and RFS.

Results: A total of 132 patients with LARC were analysed. Sarcopenia: Hazard ratio (HR) 3.71; 95% CI, 1.28-10.75, P = 0.016 was independently associated with worse Overall Survival following multivariate analysis. There was no significant relationship between sarcopenia and RFS: Time ratio (TR) 1.67; 95% CI 0.52-5.34, P = 0.386.

Conclusion: Sarcopenia was found to be an independent risk factor for worse overall survival, but not recurrence free survival, in patients with locally advanced rectal cancer undergoing neo-adjuvant chemo-radiotherapy and surgery with curative intent.

Keywords: muscle mass; neo-adjuvant chemo-radiotherapy; rectal cancer; sarcopenia; survival.

PubMed Disclaimer

References

    1. Conroy T, Lamfichekh N, Etienne P-L et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J. Clin. Oncol. 2020; 38: 4007.
    1. Cancer, Australia. Bowel cancer (colorectal cancer) in Australia statistics. NSW. [Updated 31 Aug 2022.] Available from URL: https://www.canceraustralia.gov.au/cancer-types/bowel-cancer/statistics.
    1. van Gijn W, van Stiphout R, van de Velde CJH et al. Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy. Ann. Oncol. 2015; 26: 928-35.
    1. Song J, Chen Z, Huang D et al. Nomogram predicting overall survival of resected locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy. Cancer Manag. Res. 2020; 12: 7375-82.
    1. Hopkins J, Reif R, Bigam D, Baracos V, Eurich D, Sawyer M. The impact of muscle and adipose tissue on long-term survival in patients with stage I to III colorectal cancer. Dis. Colon Rectum 2019; 62: 549-60.

LinkOut - more resources